Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -1.94
- Piotroski Score 4.00
- Grade Neutral
- Symbol (FATE)
- Company Fate Therapeutics, Inc.
- Price $4.03
- Changes Percentage (1.64%)
- Change $0.07
- Day Low $3.93
- Day High $4.14
- Year High $8.83
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell lymphoma and chronic lymphocytic leukemia; FT538 to treat AML and multiple myeloma; FT576 to treat multiple myeloma; FT819 to treat hematologic malignancies and solid tumors; FT536 to treat solid tumors; and FT500 for the treatment of advanced solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of two off-the-shelf iPSC-derived CAR T-cell product candidates; strategic research collaboration and license agreement with Juno Therapeutics, Inc. to screen for and identify small molecule modulators that enhance the therapeutic properties of genetically-engineered T-cell immunotherapies; and a collaboration and option agreement with Janssen Biotech, Inc. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 11/05/2024
- Fiscal Year End N/A
- Average Stock Price Target $7.50
- High Stock Price Target $145.00
- Low Stock Price Target $4.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$1.92
- Trailing P/E Ratio -1.92
- Forward P/E Ratio -1.92
- P/E Growth -1.92
- Net Income $-160,928,000
Income Statement
Quarterly
Annual
Latest News of FATE
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Minn. Man Who Fatally Stabbed His Wife at Bible Study Learns Fate
Robert Castillo was sentenced to 33 ⅓ years in prison for the second-degree murder of his wife, Corinna Woodhull. Despite a history of domestic violence, Castillo stabbed her during a Bible study se...
By PEOPLE.com | 1 day ago -
Woman adopts abandoned rescue dog, convinced "fate stepped in"
A heartwarming tale of love and destiny gained popularity online as a woman shared her belief that her late dog sent a new companion. Lindsay's emotional journey, from losing Reba to welcoming Tilly, ...
By Newsweek | 1 day ago -
Lamorne Morris reveals fate of a 'New Girl' reunion -- and which...
Lamorne Morris hints at a "New Girl" reunion, joking about Jake Johnson not being on board. The cast is open to the idea, but some are hesitant due to the show's satisfying ending. Morris is currently...
By New York Post | 2 days ago
